Skip to content
AnalystLens

ALTRIA GROUP, INC. 8-K Report, Regulation FD Disclosure (Oct 20, 2022)

Reports
Regulation FD·Other Events·Exhibits & Filings
Filing Date
Filed October 20, 2022
Period End
October 19, 2022
Security
MO
In the record · 2016–202610-K2110-Q328-K143

MO filed 21 annual reports (10-K), 32 quarterly reports (10-Q) and 143 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Oct ’16Oct ’16
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Leadership change8-K · Oct ’21Oct ’21
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed October 20, 2022. Cited figures are marked; the original filing is the authoritative source.

Altria Group, Inc. (MO) announced a significant strategic development regarding its U.S. commercialization rights for the IQOS Tobacco Heating System®.

On October 19, 2022, a subsidiary of Altria entered into a purchase agreement with a subsidiary of Philip Morris International Inc. (PMI) that will result in Altria assigning exclusive U.S. commercialization rights for IQOS to PMI, effective April 30, 2024. This transaction is structured with substantial financial consideration for Altria.

The company received $1.0 billiona upfront upon signing the agreement and is set to receive an additional $1.7 billion plus interest by July 15, 2023, totaling approximately $2.7 billion in cash. This move marks a material shift in Altria's involvement with the IQOS product in the U.S. market.

02—Key points

Key Highlights

  1. Altria to assign exclusive U.S. commercialization rights for IQOS to PMI, effective April 30, 2024.
  2. Total cash consideration for Altria amounts to approximately $2.7 billion.
  3. Altria received $1.0 billion upfront on October 19, 2022.
  4. An additional $1.7 billion payment is due to Altria by July 15, 2023, with interest.
  5. The agreement concludes Altria's U.S. commercialization relationship with PMI for IQOS.
  6. The filing includes forward-looking statements subject to risks and uncertainties.

03—Questions

Frequently Asked Questions

  1. What is the financial impact of this agreement on Altria?

    Altria will receive approximately $2.7 billion in total cash consideration. This includes $1.0 billion received upfront and an additional $1.7 billion plus interest expected by July 15, 2023.

  2. When will Altria cease its U.S. commercialization of IQOS?

    Altria will assign exclusive U.S. commercialization rights to PMI effective April 30, 2024.

  3. Why is Altria relinquishing U.S. IQOS rights?

    The 8-K filing states the agreement is to 'transition and ultimately conclude the relationship between Altria and PMI with respect to the IQOS System in the U.S.' The specific strategic reasons beyond this are not detailed in this filing, but it represents a significant shift in Altria's product strategy.

  4. Are there any risks associated with this transaction?

    Yes, the filing notes that the transaction is subject to risks and uncertainties, including Altria's ability to realize the expected benefits and the outcome of any potential legal proceedings or investigations related to the transaction.

04—Continue

← View all 8-K filings